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.4hstract 
In chronic myelogenous leukemia (CML) the reciprocal translocation of the long arms of chromosomes results in the formation of the unique 
BCR/ABL fusion gene which is believed to play a crucial role in the pathogenesis of CML. Different short synthetic ribozyme constructs were 
compared with regard to their efficiency to cleave the BCRlABL target RNA. In the CML cell line K562 we were able to inhibit the ~210~~~‘~~~ 
synthesis by a ribozyme which was about twofold more effective than the corresponding antisense molecule. 
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1. Introduction 
The Philadelphia chromosome, a reciprocal transloca- 
tion of chromosomes 9 and 22 is a consistant genetic 
finding in about 95% of patients with chronic myelo- 
genous leukemia (CML) [l]. The result of this event is the 
BCR/ABL fusion gene which codes for two mRNA 
types, B3A2 and B2A2, both of which are translated into 
a protein of 2 10 kDa (p2 10 BCWABL) which is unique to the 
malignant cell phenotype [2]. The increased tyrosin ki- 
nase activity of this protein and its subsequently altered 
intracellular regulatory functions play a crucial role in 
the establishment of CML as could be shown in different 
transgenic mouse models [3-51 and studies with bone 
marrow transplantation in irradiated mice transplanted 
with a BCR/ABL transfected bone marrow [6]. 
sequences, The cleavage reaction depends on the pres- 
ence of divalent metal ions at neutral or higher pH and 
results in the production of two truncated RNA mole- 
cules with 5’ hydroxyl and 2’,3’ cyclic phosphate groups 
[14,15]. 
In order to be able to cleave the B3A2-type BCR/ABL 
mRNA and to decrease the synthesis of p210BCWABL in 
the CML cell line K562, which expresses only the B3A2 
mRNA, four short ribozymes were synthesized which 
exclusively cleave this type of mRNA. The in vitro effi- 
cacy of the different ribozymes was evaluated. In addi- 
tion a pure antisense oligonucleotide without ribozyme 
activity was compared to the true ribozymes in the K562 
cell line experiments; lipofection was used as the trans- 
fection method. 
Ribozymes are capable of catalyzing RNA cleavage 
reactions in a sequence-specific way. Therefore they 
seem to be suitable tools to inhibit the expression of 
specific RNA transcripts as could already be shown with 
several different constructs [7-l 1] targeting mainly viral 
RNAs. The so-called hammerhead ribozymes contain a 
conserved region which has to be flanked at both the 5’ 
and the 3’ ends by sequences that are complementary to 
the target sequence. Using this approach almost any tar- 
get RNA can be cleaved after GUN [12] and with less 
efficiency after NUN (N = any nucleotide except G) [ 131 
2. Materials and methods 
2. I. Ribozymes 
*Corresponding author. Fax: (49) (76 1) 270 3206. 
The sequence information to construct the different ribozymes was 
taken from the published literature [16]. The different ribozymes and 
controls were synthesized from commercially available RNA phospho- 
ramidites (Milhpore, Eschbom, Germany) on a DNA/RNA synthesizer 
(Applied Biosystems, Model 394, Foster City, USA) according to the 
manufacturer’s protocol. Then the oligonucleotides were incubated in 
NH, overnight at 55’C, lyophilized and resuspended in tetrabutylam- 
moniumfluoride. Before use a final purification step by Biospin 6 col- 
umns (Bio-Rad, Richmond, USA) followed which resulted in oligonu- 
cleotides resuspended in dH,O. 
Four different ribozymes, R536, R736, R736S and R837, were tested 
in in vitro cleavage xperiments (Fig. 1). A fifth construct, R736C, was 
identical to R736, except for a G to A base exchange at position 10 
(numbering according to Williams et al. [17]); this leads to complete 
abolishment of cleavage capacity, leaving this construct as a pure anti- 
sense control. The cleavage capacity of the above mentioned ribozymes 
was compared to an in vitro transcribed NT7 ribozyme which was 
described previously [18]. 
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2.2. Transcriptions 
“S-1abeled B3A2-type BCR/ABL transcripts were synthesized from 
a pBluescript 11 derived vector as previously described [18]. 
2.3. In vitro cleavage reactions 
Radioactive transcripts and unlabeled ribozymes were incubated at 
37°C at a 1: 1 molar ratio (concentration of 50 nM) in a 20 ~1 reaction 
volume containing 50 mM Tris-HCl pH 7.5, 20 mM MgCI,, 1 mM 
EDTA and 1 U RNase Block I1 (Stratagene, La Jolla, USA). Aliquots 
of the reaction mixes were removed after I h, 6 h and 16 h incubations 
and separated in 6% denaturing polyacrylamide gels; gels were dried 
and subjected to autoradiography for 6 to 48 h using Kodak XAR film. 
The different bands corresponding to RNA fragments were quantitated 
by laser densitometry scanning (Molecular Dynamics Image Quant 
3.3). 
2.4. Cells 
K562 cells were grown in RPM1 1640 medium (G&co) supplemented 
with 10% heat inactivated fetal calf serum (Seromed), 2mM glutamine, 
10 fig/ml streptomycin and 100 U/ml penicillin; cells were kept in a 
moist atmosphere with 5% CO, at 37°C and fed three times per week. 
2.5. Ribozyme lipofection 
1 x lo7 K 562 cells were seeded into tissue culture flasks in a volume 
of 10 ml. The different ribozymes and controls were transfected with 
the lipofection agent DOTAP (Boehringer Mannheim, Germany) ac- 
cording to the manufacturer’s protocol at a tinal concentration of 0.81 
PM. After four hours the volume was adjusted to 20 ml with medium. 
Cells were harvested 72 h later. 
2.6. Detection of p210BCR’A8L 
Cells were counted and washed once in phosphate-buffered saline 
(PBS). The different aliquots were adjusted to exactly the same cell 
number (1.2 x 10’) and 12 ml of ice-cold PBSTDS (58 mM Na,HPO,, 
17 mM NaH,PO,, 68 mM NaCI, 1% Triton X-100, 0.5% sodium de- 
oxycholate, 0.1% sodium dodecyl sulfate [SDS]) was added After an 
incubation for 10 min the cells were further disrupted by repeated 
aspirations through a 21-gauge needle. After two centrifugation steps, 
one for 30 min at 1,500 rpm and one for one hour at 40,000 rpm the 
supernatant was used for immunoprecipitation with 20 ~1 of a polyclo- 
nal rabbit anti-BCR antibody [19,20] (kindly provided by J. van Den- 
deren) for 2 h at 4°C. As a control antibody we used a pig anti-rabbit- 
IgG antibody for immunoprecipitation. After adding 40 ~1 of protein 
G plus/protein A agarose beads (Dianova, Hamburg, Germany) the 
solution was incubated for 30 min at 4°C and centrifuged for 15 min 
at 2500 rpm. The pellet was washed twice in PBSTDS (without SDS) 
and finally resuspended in 50 mM Tris-HCI pH 7.0. Autophosphoryla- 
tion followed for-10 min at 30°C in a solutioncontaining 20 mM PIPES, 
DH 7.0. 20 mM MnCI, and 20 uCi of IY-‘~P~ATP. The aearose beads 
&ere washed twice in PBSTDS’(without SDS) and resuspended in 20 
~1 of gel loading buffer (65 mM Tris-HC1 pH 6.8, 2% SDS, 10% glyc- 
erol, 5% j3-mercaptoethanol, 0.1% Bromphenolblue) [21]. After heating 
at 80°C for 5 min the reaction mixture was separated by SDS-PAGE 
in a 7% gel at a constant current of 80 mA. A prestained molecular 
weight marker (Bio-Rad) was included in each gel. After electrophore- 
sis the gel was dried and quantification by laser densitometry scanning 
followed after autoradiography for 24 to 96 h. 
3. Results and discussion 
Four synthetic ribozymes with flanking regions of dif- 
ferent length (Fig. l), from 5 to 8 bases in stem III and 
9 to 10 bases in stem I as well as one construct with a 
modified stem II/loop II were compared for their effi- 
ciency to cleave the BCR/ABL target molecule. A previ- 
ously used ribozyme, NT7, which was transcribed from 
a short T7 promotor carrying gene served as comparison 
[18]. To differentiate between ribozyme and pure anti- 
sense effects in the cell line experiments we designed a 
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Fig. 1. The B3A2-type BCR/ABL RNA target, ribozymes and controls. 
The constructs differ in the lengths of the flanking regions in stems I 
and III (NT7, R837, R736, R536); R736S is identical to R736, but has 
a modified stem II; R736C has a G to A base exchange at position 10 
compared to R736, hereby destroying the cleavage capacity of the 
molecule. 
construct without cleavage capacity in which the ribonu- 
cleotide G was replaced by A at position 10, rendering 
this molecule, R736C, a pure antisense oligoribonucleo- 
tide (Fig. 1). 
The BCR/ABL target RNA transcript was cleaved 
under standard conditions for up to 16 h. A correspond- 
ing autoradiograph is shown in Fig. 2. The cleavage rate 
varied as shown in Fig. 3 and Table 1. R736 with flank- 
ing sequences of 7 bases at the 5’ end (BCR) and 9 bases 
at the 3’ end (3 BCR, 6 ABL) had the maximum cleavage 
rate (68% after 16 h) of all ribozymes tested. Ribozymes 
R.536 with a shorter stem III and R736S with a shortened 
stem II were less efficient. In the case of R536 this was 
probably due to an inability to stabilize stem III and 
subsequent early dissociation from its target. Ribozymes 
with longer stem I and/or stem III sequences were also 
less efficient than R736. 
Substrate discrimination is a critical issue concerning 
ribozyme efficiency as was discussed in detail by Hersch- 
lag [22]. Some of the theoretical aspects of this could be 
confirmed by our experiments; a ribozyme with 7 and 9 
bases in stem III and stem I had the highest cleavage rate. 
Table 1 
Cleavage rates (in percent) of the BCR/ABL target corresponding to 
the different ribozyme constructs after different ime intervals; numbers 
were calculated from Fig. 2 after quantification by laser densitometry 
scanning 
1 hour (W) 6 hours (%) 16 hours (%) 
R536 7 14 30 
R736 15 36 68 
R837 14 37 51 
R736S 21 37 57 
NT7 14 35 62 
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Fig. 2. Autoradiography of a ribozyme cleavage reaction with the different constructs. The target and the ribozyme are incubated at a concentration 
of 50 nM each. The B3A2-type BCWABL target has a length of 510 bases; products are 308 and 202 bases long. Reactions were performed in the 
absence of magnesium (lanes 1, 5, 9, 13) or with magnesium and stopped after 1 h (lanes 2, 6, 10, 14), 6 h (lanes 3, 7, 11, 15) and 16 h (lanes 4, 8, 
12, 16). 
In the case of the BCR/ABL target it was not possible 
to shorten stem I the same way as stem III due to the fact 
that the cleavage site was within BCR sequences just 4 
bases 5’ to the BCR/ABL junction. Further shortening 
of stem I might allow cleavage of normal instead of 
rearranged BCR related RNAs. 
Based on the above experiments we tested ribozyme 
R736 in the cell line K562 in order to inhibit the 
P2 1 OBCRiABL synthesis. Compared to the lipofection agent 
DOTAP (100%) and the pure antisense control R736C 
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(43%) the greatest reduction in the autokinase activity of 
P2 1 OBCWABL was observed with R736 (23%) (Fig. 4). This 
showed an almost 2-fold higher efficiency than the corre- 
sponding antisense molecule. This is in contrast to the 
results reported by Snyder et al. which showed complete 
abolishment of p2 1 OBCWABL [23]. The difference might be 
due to the greater stability of their ribozyme, as this was 
composed of a rather RNase resistant DNA/RNA hy- 
brid molecule; in addition flanking sequences of 10 bases 
in stem III (8 deoxynucleotides and 2 ribonucleotides) 
, 
NT7 0’ 
, 
1 
t 
Oh 2h 4h 6h 6h 10h 12h 14h lib 
Oh 2h 4h 6h 6h 10h 12h 14h 16h 
time 
Fig. 3. Cleavage rates of the different ribozymes (R536, R736, R837, R736S) in comparison to the in vitro transcribed NT7 ribozyme. The cleavage 
rate (in percent) is given as the ratio of the sum of the cleavage products to the sum of the cleavage products plus the remaining target after certain 
time intervals. Results were calculated from Fig. 2 after quantification by laser densitometry scanning. 
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Fig. 4. Autokinase assay ofp210 BCWABL isolated from identical numbers 
(1.2x10’) of K562 cells after incubation with ribozyme R736, the anti- 
sense oligonucleotide R736C without ribozyme activity and the lipofec- 
tion agent DOTAP alone. ‘Control’ is the same as ‘DOTAP’, but 
immunoprecipitation was done with a pig anti-rabbit-IgG antibody. 
The least amount of p210 BCR’ABL is shown with the R736 ribozyme 
(23%), about 2-fold less than with the antisense oligonucleotide R736C. 
and 8 bases in stem I (7 deoxynucleotides and 1 ribonu- 
cleotide) might favour faster dissociation of the ribozyme 
from the cleavage products as DNA/RNA helices are less 
stable than RNA/RNA helices. 
We have previously shown, that ribozymes are able to 
selectively cleave BCR/ABL rearranged RNAs [18]. In 
this report we describe the optimization of such a ri- 
bozyme; the possible large scale synthesis of such a short, 
but still very effective ribozyme, will soon allow thera- 
peutic applications as ex vivo purging of autologous 
blood stem cells. Its selectivity to destroy only the malig- 
nancy associated transcript and the fact that short func- 
tioning ribozymes, which are easily lipofected into a tar- 
get cell, do not need to be integrated as ribozyme genes 
into the genome are main advantages. 
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